Loading...
XSHE
002643
Market cap1.67bUSD
Oct 09, Last price  
12.20CNY
1D
0.00%
1Q
-31.92%
Jan 2017
-15.98%
IPO
140.82%
Name

Valiant Co Ltd

Chart & performance

D1W1MN
XSHE:002643 chart
P/E
39.28
P/S
3.01
EPS
0.31
Div yield, %
0.82%
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-3.14%
Revenues
3.72b
+0.63%
639,478,592404,874,884731,662,751820,090,562789,577,815965,382,3401,068,796,1901,631,042,5591,847,391,0812,456,391,2172,631,664,6582,870,127,6682,918,105,8894,358,522,8494,358,522,8495,080,461,9665,080,461,9654,305,320,1353,693,259,1293,716,627,622
Net income
284m
+15.51%
93,624,26963,399,33099,802,365120,241,105109,249,090123,941,59896,532,243257,847,493318,652,700385,278,437444,476,822506,707,320504,710,212626,658,928626,658,935721,333,576721,333,583763,011,991246,278,008284,480,463
CFO
1.09b
-0.58%
49,497,87864,957,95994,704,915156,068,852189,079,18866,414,783198,143,305143,375,664366,599,551152,654,463612,280,415430,702,048757,162,295558,657,0911,044,731,323982,999,6991,083,658,2281,096,284,1401,089,888,714
Dividend
Jun 11, 20260.125 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Valiant Co.,Ltd., a global enterprise established in 1992, specializes in the worldwide production and distribution of an extensive array of chemical materials. The company's diverse product portfolio primarily encompasses electronic chemicals, including components and intermediates vital for liquid crystal displays (LCDs) and organic light-emitting diodes (OLEDs), as well as polyimide (PI) materials, photoresist (PR) monomers, and crucial additives for lithium-ion batteries. Beyond electronics, Valiant provides various specialized materials for environmental and industrial applications. These include substances for automotive exhaust purification, catalysts for flue gas denitrification, volatile organic compound (VOC) adsorption, methanol-to-olefin conversion, and petroleum cracking. Furthermore, the company contributes to the new energy sector with advanced materials, energy-efficient lighting solutions, organic solar technologies, and ancillary components for electric vehicles. Valiant's operations also extend into the life sciences and healthcare domains. It manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished drug formulations, alongside traditional Chinese medicine products and nutritional health supplements. The company supports scientific research through life science products and services relevant to drug innovation, genomics, proteomics, metabolomics, and food health analysis. Additionally, Valiant develops diagnostic reagents essential for identifying human diseases such as AIDS, hepatitis, cancer, dengue fever, and cardiovascular/cerebrovascular conditions, as well as for detecting drug abuse, endocrine levels, and other physiological parameters. Originally known as Yantai Valiant Fine Chemicals Co., Ltd., the company rebranded to Valiant Co.,Ltd. in May 2015. It is headquartered in Yantai, China.

Key people

Bin Gao
Chief Financial Officer, Finance Director · since 2017
Zhongli Wang
General Manager · since 2004
Shaobang Fu
Deputy General Manager · since 2021
Baohua Hu
Deputy General Manager · since 2017
Jihua Wang
Deputy General Manager · since 2017
Huanjie Wang
Deputy General Manager · since 2020
Shumin Yu
Secretary of the Board · since 2020
Yiwu Huang
Chairman of the Board · since 2020
Zhonghe Huo
Chairman of the Board · since 2025
Shaoyang Lu
Director · since 2022
Xiaoyue Yang
Director · since 2023
Wei Zhang
Staff Elected Director · since 2025
Lianbo Zhang
Director · since 2024
Caifei Zhu
Director · since 2023
Independent Director · since 2020
Ying Guo
Independent Director · since 2021
Independent Director · since 2021
IPO date
Dec 20, 2011
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
烟台经济技术开发区五指山路11号
烟台市, SD 264006
CN
Address
11 Wuzhishan Rd.,YEDA Yantai
Yantai, SD 264006
CN
Other language
Valiant Co.,Ltd.

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT